cefaclor is the second generation of cephalosporins, and cefdinir belongs to the third generation of cephalosporins. From the second generation to the third generation, it is a process of continuous evolution, with wider antibacterial spectrum and lower toxicity.
cefdinir
cefdinir is the third generation cephalosporin, with capsules of 5mg/ capsule and 1mg/ capsule. Fujisawa Pharmaceutical Industry Co., Ltd. was originally researched, and it was first listed in Japan in 1991 under the trade name Cefzon. It was listed in the United States in December 1997, and in South Korea in 1999. In 21, domestic cefdinir was approved to be listed in China. Shanghai Anhante Biomedical Technology Co., Ltd. applied for the import of raw materials in April 29, which has been approved by SFDA. In addition, the company has found a new way with Shanghai Maibai Medical Technology Co., Ltd., and the import registration does not infringe Sanofi patent (crystal form 2) clopidogrel bisulfate crystal form 1 and other raw materials that are scarce in China.
cefaclor
cefaclor is the second generation oral cephalosporin, which has a strong killing effect on a variety of gram-positive bacteria and gram-negative bacteria. This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. The activity against Penicillinase-producing Staphylococcus aureus, Group A hemolytic streptococcus, Streptococcus viridans and Staphylococcus epidermidis is the same as that of cefadroxil, and the antibacterial activity against penicillin-producing Staphylococcus aureus and pneumococcus is 2 ~ 4 times stronger than that of cefadroxil. The activity of gram-negative bacilli including Escherichia coli and Klebsiella pneumoniae is stronger than cefalexin, similar to cefadroxil, and stronger than cefadroxil for Proteus mirabilis, Salmonella and Shigella. 2.9 ~ 8 mg/L of this product can inhibit all Haemophilus influenzae, including ampicillin-resistant strains.